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Introduction {#sec1}
============

LC-PUFAs, including ω-3 and ω-6, are essential fatty acids to mammals that cannot be synthesized *de novo*. The ω-6 arachidonic acid, ω-3 eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) are obtained through the diet either directly or as their precursors, linoleic acid and alpha-linolenic acid. Bioconversion of LC-PUFAs from their precursors is mediated by desaturases encoded by fatty acid desaturase 1 (*FADS1*) and *FADS2* in the *FADS* gene cluster and elongases encoded by *ELOVL* fatty acid elongase 2 (*ELOVL2*) and *ELOVL5* ([@bib31], [@bib45]).

Disrupting any of the desaturases and elongases blocked the *in vivo* synthesis of LC-PUFAs, which significantly affected normal growth and development in mouse models ([@bib10], [@bib29], [@bib36], [@bib44]). Recently, the ELOVL2 enzyme, in addition to FADS2, was verified to be another key enzyme in the synthesis of DHA *in vivo* ([@bib12], [@bib32], [@bib33]). SNPs in the *ELOVL2* locus are strongly associated with levels of LC-PUFA-derived metabolites in blood in many GWAS and meta-analyses ([Table S1](#mmc1){ref-type="supplementary-material"}). Minor alleles of SNPs in the *ELOVL2* locus were associated with higher levels of EPA and DPA and lower levels of DHA in plasma phospholipids, suggesting carriers of the minor alleles have lower efficiency in the bioconversion cascade from EPA to DPA and DHA catalyzed by the ELOVL2 enzyme ([@bib20], [@bib37]). The identification of genetic determinants of plasma and tissue lipid levels is a key enabling factor for successful future personalized medicine interventions with EPA/DHA supplements ([@bib7]). The recent successful outcome of REDUCE-IT illustrates the value of evaluating the effects of EPA/DHA treatment on specific patient segments (hypertriglyceridemia and related lipoprotein abnormalities selected biochemically or genetically) with elevated risk that is believed to be at least partly attributable to an elevated level of the target of the intervention ([@bib3]).

The identification of functional variants behind GWAS is hindered by the linkage disequilibrium (LD) in associated regions. To prioritize the variants in LD with reported SNPs in GWAS for functional validation, we developed an allele-specific (AS)-SNPs pipeline ([@bib5]). This pipeline utilizes the available chromatin immunoprecipitation coupled with massively parallel sequencing (ChIP-seq) data from the Encyclopedia of DNA Elements (ENCODE) project to detect variants located in regulatory regions and that showed allelic imbalance in chromatin binding by different transcription factors (TFs) ([@bib39]).

Liver is the most important organ for LC-PUFAs synthesis and *ELOVL2* is also highly expressed in the liver. We hypothesized that the observed association of LC-PUFA profiles in blood to the *ELOVL2* locus is mainly reflecting the differences in LC-PUFAs metabolism in the liver. Among all the AS-SNPs identified in human liver HepG2 cells, rs953413 located in the first intron of *ELOVL2* showed significant allelic imbalance in chromatin binding. In the present study, we found that rs953413, located in an evolutionarily conserved enhancer element, directly regulates *ELOVL2* expression by mediating the cooperative binding between FOXA and HNF4α factors and that it is an important contributor to the observed difference in LC-PUFAs levels among carriers of different alleles in GWAS.

Results {#sec2}
=======

Prioritization of Candidate Regulatory Variations in the *ELOVL2* Locus {#sec2.1}
-----------------------------------------------------------------------

The reported SNPs in the *ELOVL2* locus span a region of ∼90kb that totally covers the gene body of *ELOVL2* and are observed to be in high LD in the European populations ([Figure S1](#mmc1){ref-type="supplementary-material"}). The alleles of the reported SNPs in LD with the major G allele of rs953413 were generally associated with a more efficient synthesis of LC-PUFAs from their precursors, e.g. synthesis of DHA from EPA and DPA ([@bib9], [@bib15], [@bib20], [@bib22], [@bib37]). To pinpoint the true causal variants in the *ELOVL2* locus, fine mapping of variants in this region to a 99% credible set was carried out in a trans-ethnic meta-analysis in Chinese- and European-ancestry populations ([@bib14]). A total of 123 potential regulatory variations were identified in the HaploReg database that are in LD (r^2^ \> 0.8 in 1,000 Genomes Pilot I) with the SNPs in the credible set led by rs3798713 for EPA, rs9393915 for DPA, and rs953413 for DHA ([@bib14]). As liver is the most important organ for *in vivo* synthesis of LC-PUFAs, we hypothesized that the observed association of LC-PUFA profiles in blood to the *ELOVL2* locus is mainly reflecting the differences in LC-PUFAs metabolism in the liver. Only the potential regulatory variants that are annotated to be located in active promoter or enhancer regions in the liver that consist of 47 variations were kept for further consideration ([Figure 1](#fig1){ref-type="fig"}A; detailed information on variations is listed in [Table S2](#mmc1){ref-type="supplementary-material"}).Figure 1SNP rs953413 Locates in an Active Enhancer Region to Regulate Its Enhancer Activity(A) Both rs953413 and rs3798713 are located in highly active DNase I hypersensitivity sites that are also enriched with H3K27ac signals in HepG2 cells. The candidate regulatory SNPs in the *ELOVL2* locus selected from the credible set that are located in regulatory regions in the liver are listed.(B and C) The G allele of rs953413 showed significant higher enhancer activity compared with the A allele in luciferase assay coupled with both the MP (B) and SV40 promoter (C). Error bars, s.d. *n* = 6 from two independent plasmid extractions and transfections with each transfection had three technical replicates.(D) The rs953413 region is enriched with H3K27ac signal in both HepG2 and PLC/PRF/5 cells compared with the negative control region GDCHR12 in ChIP-qPCR. The HNF1α-pro is employed as the positive control. Error bars, s.d. *n* = 3 technical replicates. In B--D, \*\*p \< 0.01 evaluated using two-tailed Student\'s *t* tests.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

To further prioritize the identified regulatory variants, we intersected the 47 regulatory variants with SNPs in the *ELOVL2* locus that showed allelic imbalance in chromatin binding identified by the AS-SNPs pipeline in HepG2 cells. A total of three SNPs in the *ELOVL2* locus including rs953413, rs3798713, and rs17675073 were identified to be AS-SNPs in HepG2 cells that showed allelic imbalance in chromatin binding for FOXA1 and FOXA2 ([Table S3](#mmc1){ref-type="supplementary-material"}) ([@bib4]). As both rs953413 and rs3798713 were identified to be lead SNPs in the calculated credible set and showed allelic imbalance in chromatin binding for FOXA1 and FOXA2, they were selected for further functional validation.

rs953413 Resides in a Liver-Specific Enhancer {#sec2.2}
---------------------------------------------

The *ELOVL2* locus has copy number variation (CNV) in HepG2 cells, which has two copies of chromosome bearing the G allele of rs953413 ([@bib24], [@bib46]). To verify that the observed allelic imbalance in rs953413 and rs3798713 is not only caused by the CNV and to identify candidate causal TFs, we employed a more stringent strategy that filtered out PCR duplicates and tolerated no mismatch other than the SNP itself to each TF that mapped to these two regions in ChIP-seq experiments in HepG2 cells. Among all the TFs that have peaks overlapping or nearby rs953413 and rs3798713, only FOXA1 and FOXA2 showed reproducible allelic imbalance in chromatin binding with a preference for the G alleles of rs953413 and rs3798713 ([Table S3](#mmc1){ref-type="supplementary-material"}). In accordance with occupation by multiple TFs, both the rs953413 region and rs3798713 region are highly enriched with H3K27ac signals and are also located in active DNase I hypersensitivity sites in HepG2 cells ([Figure 1](#fig1){ref-type="fig"}A). Additionally, both the rs953413 region and rs3798713 region are observed to directly interact with the promoter region of *ELOVL2* identified by Capture Hi-C in GeneHancer, suggesting that these regions may be actively involved in *ELOVL2* regulation ([Figure 1](#fig1){ref-type="fig"}A) ([@bib11]).

We next performed luciferase assay to test the enhancer activity of the two selected regions. As rs17675073 is in proximity to rs3798713, we amplified a 287-bp fragment encompassing both SNPs and inserted upstream of the minimal promoter (MP) to test its ability to drive luciferase expression. This region did show enhancer activity compared with the control plasmid without insertion. However, neither of the SNPs showed significant differences between alleles conditional on the other SNP ([Figure S2](#mmc1){ref-type="supplementary-material"}). This region was then discarded for further analysis. For the rs953413 region, the enhancer activity was tested with a 529-bp fragment with rs953413 located in the middle. Both alleles of rs953413 were observed to have strong enhancer activity in cooperation with the MP in driving luciferase expression. The G allele of rs953413 had a significantly higher enhancer activity compared with the A allele ([Figure 1](#fig1){ref-type="fig"}B). This difference in enhancer activity between alleles of rs953413 was further validated with the SV40 promoter in the other luciferase construct ([Figure 1](#fig1){ref-type="fig"}C).

The meta-analysis carried out in the CHARGE Consortium provided us with the comprehensive association results for ω-3 fatty acids in plasma phospholipid in the *ELOVL2* locus ([@bib20]). rs953413 and its proxies (r^2^ \> 0.8 in 1,000 Genomes phase 3) generally showed stronger association with EPA, DPA, and DHA levels compared with other SNPs ([Figure S3](#mmc1){ref-type="supplementary-material"}). In addition, the rs953413 region showed tissue-specific H3K27ac signals with enrichment of H3K27ac binding only observed in HepG2, A549, and PANC-1 cells from all the available cell lines in the ENCODE project ([Figure S4](#mmc1){ref-type="supplementary-material"}). The enrichment of H3K27ac over the rs953413 region was further validated with ChIP followed by quantitative real time (ChIP-qPCR) in liver cancer cell lines HepG2 and PLC/PRF/5 ([Figure 1](#fig1){ref-type="fig"}D). The enrichment of H3K27ac signal together with enrichment of TFs binding to the rs953413 region only in liver cells support the idea that the rs953413 region shows liver-specific enhancer feature ([Figure S4](#mmc1){ref-type="supplementary-material"}). Interestingly, although not coming to genome-wide significant level, carriers of the G allele of rs953413 were observed to have higher expression of *ELOVL2* (p = 1.4 × 10^−4^) in liver tissues from the GTEx project ([Figure S5](#mmc1){ref-type="supplementary-material"}) ([@bib1]). This observation coupled with the preferential binding of FOXA1 and FOXA2 to the G allele of rs953413 suggests that rs953413 may regulate *ELOVL2* expression by modulating the enhancer activity of the rs953413 region in liver, which further affects the synthesis of LC-PUFAs.

The rs953413 Region Is Evolutionarily Conserved {#sec2.3}
-----------------------------------------------

To identify the causal TFs mediating the difference in enhancer activity in the rs953413 region, we first isolated the minimal enhancer (ME) element for this region. A series of truncation and deletion luciferase constructs were made with both genotypes of the original 529-bp fragments as templates and inserted upstream of the MP sequence as in [Figure 1](#fig1){ref-type="fig"}B. The ME element was mapped to a 184-bp fragment (Fragment 4) that showed strong enhancer activity while keeping the sequence at minimum ([Figure 2](#fig2){ref-type="fig"}A). This ME element includes a region of around 80-bp in length that is highly conserved in vertebrates and is essential for the observed enhancer activity as only luciferase constructs containing the whole conserved region (the original 529-bp fragment, Fragment 1, 4, and Truncate 3) showed strong enhancer activity. The sequences surrounding rs953413 are less conserved in vertebrates but are also essential for the enhancer activity as the luciferase construct containing only the evolutionarily conserved region (Truncate 2) had drastically decreased enhancer activity compared with luciferase construct containing both the conserved element and the rs953413 surrounding sequence (Truncate 3) ([Figure 2](#fig2){ref-type="fig"}A).Figure 2Fine Mapping of the ME Element of the rs953413 Region to an Evolutionarily Conserved Region that Is Enriched with Putative Binding Sites for Both FOXA and HNF4α(A) The ME element is fine mapped to an evolutionarily conserved region encompassing rs953413 (Fragment 4) by luciferase assay with a series of truncation and deletion constructs from the original 529-bp fragment. The Conservation track showed the phastCons score for 100 species from the ENCODE project.(B) The ME element was predicted to have multiple conserved binding sites for both FOXA and HNF4α. The basewise conservation score for 100 species from the ENCODE project is displayed on top of the sequence. The luciferase constructs with mutations introduced into the predicted motif sequences are generated by site-directed mutagen and listed at the bottom. The introduced mutations for each mutation construct are listed as lower-case letters with dash line standing for identical nucleotides. For the deletion construct (Del), the deleted region is marked with star character.(C) The enhancer activity of the rs953413 region is significantly decreased by mutations introduced into the predicted binding sites for HNF4α and FOXA factors (as illustrated in B) in luciferase assay. Luciferase construct Fragment 4 bearing the G allele of rs953413 was employed as template for mutation. For A and C, error bars, s.d. *n* = 6 technical replicates from two independent plasmid extractions and transfections with each transfection had three technical replicates. \*p \< 0.05; \*\*p \< 0.01 calculated by two-tailed Student\'s *t* tests.

We then searched for TFs predicted to bind differently to the rs953413 region with the ME element as template and using the TRAP tool with position weight matrices (PWMs) from both the JASPAR database and literature as references ([@bib28], [@bib40]). In accordance with the observed allelic imbalance in chromatin binding for FOXA1 and FOXA2 in ChIP-seq, we identified multiple highly conserved FOXA motifs together with two conserved HNF4α motifs in the ME element ([Figure 2](#fig2){ref-type="fig"}B). The predicted motifs are located in evolutionarily conserved sequences denoted by the basewise conservation in 100 vertebrates from the ENCODE project ([Figure 2](#fig2){ref-type="fig"}B). The variant rs953413 is predicted to be located in two closely located motifs bound by FOXA and HNF4α indicative of cooperative binding by these TFs ([@bib16]).

We next examined the effect of the predicted TF binding sites on the enhancer activity of the rs953413 region by site-directed mutagenesis. Fragment 4 bearing the G allele of rs953413 and containing the whole ME element was employed as the template for construction of mutants ([Figure 2](#fig2){ref-type="fig"}B). We observed that introducing mutations at any of the predicted TF binding sites significantly decreased the enhancer activity of the rs953413 region ([Figure 2](#fig2){ref-type="fig"}C). The enhancer activity was completely depleted when mutations were introduced to the predicted binding sites in highly conserved region (constructs FX-mut1 and HF-mut1). Notably, introducing mutations to the predicted binding sites overlapping with rs953413 (constructs FX-mut4, HF-mut2, and Del) also severely decreased the enhancer activity, suggesting that rs953413 is functional in determining the enhancer activity of this region ([Figures 2](#fig2){ref-type="fig"}B and 2C).

FOXA1 and FOXA2 Regulates *ELOVL2* Expression by Binding to the rs953413 Region {#sec2.4}
-------------------------------------------------------------------------------

We next examined if both *FOXA1* and *FOXA2* are directly involved in the regulation of the enhancer activity of the rs953413 region. In accordance with our motif prediction, the minimal region that responds to both *FOXA1* and *FOXA2* induction is mapped to the luciferase construct containing the whole ME element (Fragment 4) from a series of deletion constructs in luciferase assay ([Figure S6](#mmc1){ref-type="supplementary-material"}). Both alleles of rs953413 were highly induced by both *FOXA1* and *FOXA2* overexpression ([Figure 3](#fig3){ref-type="fig"}A). The difference in enhancer activity between alleles of rs953413 was significantly compromised by *FOXA* overexpression probably due to presence of multiple conserved FOXA binding sites in this region. The responses to both *FOXA1* and *FOXA2* overexpression were significantly decreased by introducing mutations to the predicted FOXA binding sites in luciferase construct Fragment 4 bearing the G allele of rs953413. Introducing mutations to the predicted HNF4α binding sites also made this region less responsive to both *FOXA1* and *FOXA2* overexpression with significantly decreased enhancer activities compared with the wild type ([Figure 3](#fig3){ref-type="fig"}B). Especially, the response to *FOXA1*/*FOXA2* overexpression was completely depleted in luciferase construct HF-mut1 with one of the predicted HNF4α binding sites being mutated, suggesting that binding of both FOXA1/FOXA2 and HNF4α to the rs953413 region is essential for the enhancer activity.Figure 3FOXA Factors Directly Bind to the ME Element and Confer Allelic Imbalance in *ELOVL2* Expression Induced by rs953413(A) The enhancer activity of the rs953413 region is highly induced by both *FOXA1* and *FOXA2* overexpression in luciferase assay.(B) The response to either *FOXA1* or *FOXA2* overexpression is significantly compromised by the mutations introduced into the predicted binding sites for HNF4α and FOXA factors in luciferase assay. In A and B, error bars, s.d. *n* = 6 technical replicates from two independent plasmid extractions and transfections with each transfection had three technical replicates.(C) Both FOXA1 and FOXA2 are highly enriched in the rs953413 region verified by ChIP-qPCR in both HepG2 and PLC/PRF/5 cells. Error bars, s.d.(D and E) FOXA1 and FOXA2 favor binding to the G allele of rs953413 as determined by ChIP followed by AS-qPCR (D) and ChIP followed by PCR amplification and Sanger sequencing (E) in both HepG2 and PLC/PRF/5 cells. The input for ChIP was used as the control. \*p \< 0.05 and \*\*p \< 0.01 calculated by two-tailed Student\'s *t* tests. Error bars, s.d. In C and D, *n* = 4 for HepG2 cells and *n* = 3 for PLC/PRF/5 cells.(F) The G allele of rs953413 is also significantly more enriched with H3K27ac signal compared with the A allele determined by ChIP followed by AS-qPCR. *n* = 3. Error bars, s.d. \*\*p \< 0.01 calculated by two-tailed Student\'s *t* tests.(G) The expression of *ELOVL2* is significantly downregulated by *FOXA1* knockdown in HepG2 and PLC/PRF/5 cells.(H) The allelic imbalance in *ELOVL2* expression is significantly decreased by *FOXA1* knockdown in HepG2 cells. The raw ratios are shown here without correcting for the CNV. In G and H, \*\*p \< 0.01 and ns, not significant, calculated by two-tailed Student\'s *t* tests. Error bars, s.d. *n* = 8 technical replicates.See also [Figures S6--S8](#mmc1){ref-type="supplementary-material"}.

We next assessed the *in vivo* binding of both FOXA1 and FOXA2 to the rs953413 region through ChIP-qPCR. In accordance with the enrichment of ChIP-seq signals for both FOXA1 and FOXA2 in this region in HepG2 cells from the ENCODE project, the rs953413 region was observed to be highly enriched with FOXA1 and FOXA2 binding in parallel with the positive control region HNF1α-pro after normalization with the negative control region GDCHR12 in both HepG2 and PLC/PRF/5 cells ([Figure 3](#fig3){ref-type="fig"}C). To address whether FOXA1/FOXA2 showed allele-specific DNA binding at rs953413 *in vivo*, we conducted ChIP followed by allele-specific qPCR (AS-qPCR). The allele-specific amplification of each allele was achieved with primers designed following mismatch amplification mutation assay (MAMA) and validated with genomic DNA from samples bearing different genotypes at rs953413 as templates ([Figure S7](#mmc1){ref-type="supplementary-material"}) ([@bib6], [@bib21]). In accordance with the observed preference for the G allele in ChIP-seq experiments, both FOXA1 and FOXA2 were identified to be preferentially bound to the G allele of rs953413 in ChIP followed by AS-qPCR in both HepG2 and PLC/PRF/5 cells ([Figure 3](#fig3){ref-type="fig"}D). This allelic imbalance in chromatin binding for both FOXA1 and FOXA2 at the rs953413 region was further confirmed with Sanger sequencing analysis of the rs953413-containing region in chromatin fragments immunoprecipitated with antibody against both FOXA1 and FOXA2 compared with that in the input genomic DNA as control ([Figure 3](#fig3){ref-type="fig"}E). Additionally, the G allele of rs953413 was significantly more enriched with H3K27ac signal compared with the A allele in ChIP samples from [Figure 1](#fig1){ref-type="fig"}D in both HepG2 and PLC/PRF/5 cells, suggesting more of FOXA binding in this region leading to stronger enhancer activity ([Figure 3](#fig3){ref-type="fig"}F).

To determine if *FOXA1* and *FOXA2* are directly involved in regulation of *ELOVL2* expression, we next performed lentiviral-mediated *FOXA1* knockdown through short hairpin RNA (shRNA) and artificial microRNA (amiRNA) in HepG2 and PLC/PRF/5 cells ([@bib23]). Knockdown of *FOXA1* significantly decreased the expression of *ELOVL2* in both cells after normalization to reference genes *RSP18*, *ACTB*, and *GAPDH*, respectively ([Figures 3](#fig3){ref-type="fig"}G and [S8](#mmc1){ref-type="supplementary-material"}). The expression of *FOXA2* is significantly increased by *FOXA1* knockdown in HepG2 cells, whereas it is observed to be significantly downregulated by *FOXA1* knockdown in PLC/PRF/5 cells, indicative of cell heterogeneity between these two cells. The A allele of exonic SNP rs2295601 of *ELOVL2* is on the same haplotype as the A allele of rs953413 evaluated with the data from the 1,000 Genomes Project ([@bib27]). The efficiency and specificity of AS-qPCR assay targeting rs2295601 was validated with genomic DNA from the same set of samples for rs953413 AS-qPCR as templates ([Figure S7](#mmc1){ref-type="supplementary-material"}). We have evidence that FOXA1/FOXA2 favor binding to the G allele of rs953413 ([Figures 3](#fig3){ref-type="fig"}D and 3E). We therefore evaluated whether this allele-specific binding caused allelic imbalance in *ELOVL2* expression with rs2295601 AS-qPCR in HepG2 cells, which is heterozygous at this location, whereas PLC/PRF/5 was identified to be homozygous with the G allele. This analysis identified that the G allele of rs2295601 in linkage with the G allele of rs953413 was selectively transcribed in HepG2 cells. Knockdown of *FOXA1* significantly diminished the allelic imbalance in *ELOVL2* expression ([Figure 3](#fig3){ref-type="fig"}H).

HNF4α Regulates *ELOVL2* Expression through Interacting with the rs953413 Region {#sec2.5}
--------------------------------------------------------------------------------

We next assessed whether HNF4α is also directly involved in *ELOVL2* regulation through interacting with the rs953413 region. We observed that luciferase construct (Fragment 5) encompassing both of the predicted HNF4α binding sites was highly induced by *HNF4α* overexpression ([Figure 4](#fig4){ref-type="fig"}A). To refine the *HNF4α* responsive regions, truncation and deletion luciferase constructs were further constructed and subjected to *HNF4α* overexpression in luciferase assay. In accordance with our prediction, only constructs containing the predicted HNF4α-binding sites (Fragment 5, Truncate 4 and 5) were induced by *HNF4α* overexpression. To map the sequences needed for *HNF4α* induction, we introduced mutations to either of the predicted HNF4α sites with Fragment 5 as template that led to drastically diminished *HNF4α* induction ([Figure 4](#fig4){ref-type="fig"}B). Intriguingly, the Del construct (as illustrated in [Figure 2](#fig2){ref-type="fig"}B) with the predicted binding sites for HNF4α and FOXA factors surrounding rs953413 being removed completely abolished the *HNF4α* induction, suggesting rs953413 is directly located in one functional HNF4α-binding site.Figure 4HNF4α regulates *ELOVL2* Expression by Directly Binding to the ME Element and Confers Allelic Imbalance in *ELOVL2* Expression by rs953413(A) Both of the predicted HNF4α binding sites in the ME element are essential for the maximal induction by *HNF4α* in luciferase assay.(B) Disruption either of the predicted HNF4α-binding sites significantly decreased the enhancer activity induced by *HNF4α* in luciferase assay. In A and B, error bars, s.d. *n* = 6 technical replicates from two independent plasmid extractions and transfections with each transfection had three technical replicates.(C) The rs953413 region is highly enriched with HNF4α binding compared with GDCHR12 in ChIP-qPCR. Error bars, s.d.(D and E) HNF4α favors binding to the G allele of rs953413 relative to the A allele as determined by ChIP followed by AS-qPCR (D) and ChIP followed by PCR amplification and Sanger sequencing (E) in both HepG2 and PLC/PRF/5 cells. The input for ChIP was used as the control. \*\*p \< 0.01 calculated by two-tailed Student\'s *t* tests. Error bars, s.d. In C and D, *n* = 4 for HepG2 cells and *n* = 3 for PLC/PRF/5 cells.(F) The expression of *ELOVL2* is significantly decreased by *HNF4α* knockdown in both HepG2 and PLC/PRF/5 cells.(G) The allelic imbalance in *ELOVL2* expression is significantly decreased by *HNF4α* knockdown in HepG2 cells. The raw ratios are shown here without correcting for the CNV. In F and G, error bars, s.d. *n* = 8 technical replicates.See also [Figures S7](#mmc1){ref-type="supplementary-material"} and [S9](#mmc1){ref-type="supplementary-material"}.

We next performed ChIP-qPCR assays with antibody against HNF4α in both HepG2 and PLC/PRF/5 cells. In accordance with the data from the ENCODE project, we confirmed HNF4α chromatin binding at the rs953413 region and at the positive HNF1α-pro region after normalization with GDCHR12 ([Figure 4](#fig4){ref-type="fig"}C). To address whether HNF4α showed allele-specific DNA binding at rs953413 *in vivo*, we conducted ChIP followed by rs953413 AS-qPCR. This analysis showed that HNF4α was preferentially bound to the G allele of rs953413 in both HepG2 and PLC/PRF/5 cells ([Figure 4](#fig4){ref-type="fig"}D). Consistent with this finding, Sanger sequencing analysis of the rs953413-containing region showed that the G allele was enriched in chromatin fragments immunoprecipitated with antibody against HNF4α compared with the input genomic DNA as control in both cells ([Figure 4](#fig4){ref-type="fig"}E). We next performed lentiviral-mediated *HNF4α* knockdown through shRNA and amiRNA to test its effect on *ELOVL2* expression ([@bib23]). Knockdown of *HNF4α* resulted in significantly decreased expression of *ELOVL2* after normalization to reference genes *RSP18*, *ACTB,* and *GAPDH*, respectively ([Figures 4](#fig4){ref-type="fig"}F and [S9](#mmc1){ref-type="supplementary-material"}). We then performed rs2295601 AS-qPCR to evaluate if the allelic imbalance in *ELOVL2* expression was affected by *HNF4α* knockdown. After *HNF4α* knockdown, the allelic imbalance in *ELOVL2* expression was also observed to be significantly decreasing ([Figure 4](#fig4){ref-type="fig"}G).

Cooperation between HNF4α and FOXA Factors Determine the Enhancer Activity of the rs953413 Region {#sec2.6}
-------------------------------------------------------------------------------------------------

As both HNF4α and FOXA factors are bound to the rs953413 region and essential for its enhancer activity, we hypothesized that HNF4α and FOXA factors may cooperate with each other in a complex to determine the enhancer activity of the rs953413 region, which further regulates *ELOVL2* expression. To test this hypothesis, we first carried out luciferase assay overexpressing both *HNF4α* and *FOXA* factors together with luciferase construct Fragment 4 containing the whole ME element. Compared with overexpression of *HNF4α* alone or either *FOXA1* or *FOXA2* alone, the enhancer activities of both alleles of rs953413 were significantly increased by overexpression of *HNF4α* together with either *FOXA1* or *FOXA2,* indicative of cooperation between these TFs in determining the enhancer activity of the rs953413 region ([Figures 5](#fig5){ref-type="fig"}A and [S10](#mmc1){ref-type="supplementary-material"}).Figure 5Cooperation between HNF4α and FOXA Factors Determines the Enhancer Activity of the rs953413 Region and *ELOVL2* Expression(A) The enhancer activity of the rs953413 region was significantly increased by simultaneous overexpression of *HNF4α* and *FOXA1* compared with overexpression of only *HNF4α* or *FOXA1* in luciferase assay. Error bars, s.d. *n* = 6 technical replicates from two independent plasmid extractions and transfections with each transfection had three technical replicates.(B--D) Double knockdown of both *HNF4α* and *FOXA1* led to a significant decrease in *ELOVL2* expression compared with knockdown only *HNF4α* or *FOXA1* (B). This double knockdown also significantly downregulated *FOXA2* expression in both HepG2 cells (C) and PLC/PRF/5 cells (D).(E and F) The allelic imbalance in *ELOVL2* expression shown in E is gradually increased by the gradual decreases in expression of *HNF4α* and *FOXA1*/*FOXA2* in different double-knockdown HepG2 cells as shown in F. In B--F, \*\*p \< 0.01 calculated by two-tailed Student\'s *t* tests. Error bars, s.d. *n* = 4 technical replicates.See also [Figures S10](#mmc1){ref-type="supplementary-material"} and [S11](#mmc1){ref-type="supplementary-material"}.

To determine the effect of the cooperation between HNF4α and FOXA factors on *ELOVL2* expression, we generated HepG2 and PLC/PRF/5 cells with both *HNF4α* and *FOXA1* being knocked down. This double knockdown was achieved with either sequential or simultaneous transduction of lentivirus for *HNF4α* and *FOXA1* knockdown. The double knockdown cells produced with simultaneous knockdown were named FOXA1 + HNF4α KD. FOXA1-KD + HNF4α-KD denotes cells first transduced with lentivirus for *FOXA1* knockdown followed by *HNF4α* knockdown and vice versa for HNF4α-KD + FOXA1-KD. To be comparable, the control cells and cells with knockdown of only *FOXA1* or *HNF4α* were also subjected to two rounds of lentiviral transduction. Compared with knockdown of only *HNF4α* or *FOXA1*, this double knockdown strategy led to significant downregulation of not only *HNF4α* and *FOXA1* but also *FOXA2* in both cells after normalization to reference genes *RSP18*, *ACTB,* and *GAPDH*, respectively ([Figures 5](#fig5){ref-type="fig"}B--5D and [S11](#mmc1){ref-type="supplementary-material"}). It is noteworthy that the degree of knockdown for all the three TFs is much stronger compared with single knockdown in HepG2 cells ([Figure 5](#fig5){ref-type="fig"}C). As *HNF4α* and *FOXA1*/*FOXA2* are all members of the hepatocyte nuclear factor family, the cross-regulation of one another and the synergy in gene regulation has been well studied ([@bib19]). We investigated ChIP-seq signals for histone modifications (H3K4me3 and H3K27ac) in HepG2 cells indicating promoters and enhancers over the gene bodies of all the three TFs. We found that ChIP-seq signals for all the three TFs are enriched over the active chromatin regions of each TF\'s gene body indicative of coregulation of all the three TFs by themselves ([Figure S12](#mmc1){ref-type="supplementary-material"}). Coupling to the knockdown of all the three TFs, the expression of *ELOVL2* was significantly downregulated compared with knockdown of only *HNF4α* or *FOXA1* in both HepG2 and PLC/PRF/5 cells ([Figures 5](#fig5){ref-type="fig"}B and [S11](#mmc1){ref-type="supplementary-material"}). In addition, contrary to the observed decrease in allelic imbalance in *ELOVL2* expression after knockdown of only *HNF4α* or *FOXA1 in* HepG2 cells, the triple knockdown led to a significant increase in the allelic imbalance in *ELOVL2* expression ([Figure 5](#fig5){ref-type="fig"}E). Interestingly, the degree of allelic imbalance in *ELOVL2* expression was tightly associated with the degree of downregulation of the three TFs, indicating that the G allele of rs953413 is preferentially bound by these TFs when the availability of these TFs is limited, which further determines the allelic imbalance in *ELOVL2* expression ([Figure 5](#fig5){ref-type="fig"}F).

The rs953413 Region Works as a Key Enhancer Region for *ELOVL2* Regulation {#sec2.7}
--------------------------------------------------------------------------

To provide more direct evidence that the rs953413 region is involved in *ELOVL2* regulation, we first conducted CRISPR/Cas9-mediated mutagenesis of this region in HepG2 cells. Two guide RNAs were designed to cut the flanking sequences on both sides of the ME element to delete the whole rs953413 region ([Figure 6](#fig6){ref-type="fig"}A). After selecting multiple colonies, we did not get single colonies homozygous with each allele of the ME element being deleted due to the existence of CNV in this region. However, we observed that the expression of *ELOVL2* together with the allelic imbalance in *ELOVL2* expression was significantly different among different single colonies with different mutation profiles in the rs953413 region ([Figure 6](#fig6){ref-type="fig"}B). To determine the causal relationship between the mutations introduced into the rs953413 region with *ELOVL2* expression, we selected nineteen single colonies with different mutation profiles for further characterization. Sanger sequencing on direct PCR product amplified from the rs953413 region was carried out from both sides to determine the mutation pattern for each colony together with multiple (from 5 to 26) TA clones of PCR product to determine the genotype of each colony. From all the selected colonies, we successfully identified the genotypes of twelve colonies, with the others either having multiple alleles detected or missing the A allele of rs953413 detected.Figure 6CRISP/Cas9-mediated Mutation of the ME Element Impairs *ELOVL2* Expression in an Allele-Specific Manner(A) Schematic illustrating CRISP/Cas9-mediated mutation of the ME element by double gRNA. The ME element is highlighted in blue color. The binding sites for the primer pair used to validate mutations are indicated.(B) Representative gel image showing PCR amplification of the rs953413 region in selected individual clones displayed varieties of mutations introduced by the CRISP/Cas9 system.(C) Individual clones are grouped by the position of mutations introduced.(D) Clones with mutations introduced into the ME element of the rs953413 region (mut, *n* = 8) had significantly decreased expression level of *ELOVL2* compared with clones without key mutations introduced (control, *n* = 4). WT denotes the *ELOVL2* expression level in normal HepG2 cells.(E) The allelic imbalance in *ELOVL2* expression is decreased in a dosage dependent manner by mutations introduced into the ME element bearing the G allele of rs953413. For D and E, each clone had three technical replicates.(F) Schematic illustrating AS-gRNA targeting rs953413 locus.(G) Experimental time line for lentiviral transduction and antibiotic selection of HepG2 cells with lentiviral dCas9-effector and AS-gRNA.(H--L) (H and I) Changes in *ELOVL2* expression (H) and the coupled changes in allelic imbalance in *ELOVL2* expression (I) following transduction of dCas9-KRAB and dCas9-VP64 together with AS-gRNA. In H and I, \*\*p \< 0.01 and ns, not significant, calculated by two-tailed Student\'s *t* tests. Error bars, s.d. *n* = 4 technical replicates (J--L). Each AS-gRNA preferentially mutated respective allele of rs953413 when coupled with wild-type Cas9 (J), which significantly downregulated *ELOVL2* expression (K) in an allele-specific manner (L). In J--L, \*\*p \< 0.01 calculated by two-tailed Student\'s *t* tests. Error bars, s.d. *n* = 4 in J and *n* = 12 technical replicates in K and L.(M) Graphic representation of the regulatory relationships between HNF4α/FOXA, rs953413, and *ELVOL2*. HNF4α/FOXA binds to the evolutionarily conserved rs953413 region in the intron of *ELOVL2* and regulates the expression of *ELVOL2*. The G allele of rs953413 results in increased HNF4α/FOXA binding and thus upregulates *ELVOL2* expression, which consequently leads to increased synthesis of LC-PUFAs.See also [Figures S16--S19](#mmc1){ref-type="supplementary-material"}.

Our previous findings suggest that the predicted binding sites for FOXA factors are essential for the enhancer activity of the rs953413 region as mutation construct FX-mut1 completely lost the enhancer activity and its response to both *FOXA1* and *FOXA2* induction in luciferase assay ([Figure 3](#fig3){ref-type="fig"}B). The twelve colonies can generally be categorized into two groups based on the location of the mutations introduced. The alleles of the control group only have mutations flanking the ME element and the mut group have mutations to the ME element that also disrupted the predicted binding sites for FOXA factors as in mutation construct FX-mut1 ([Figure 6](#fig6){ref-type="fig"}C). Four colonies were categorized as control ([Figure S13](#mmc1){ref-type="supplementary-material"}) and eight colonies fell into the category of mut with five colonies having critical mutations in one copy of the ME element bearing the G allele of rs953413 (G1; [Figure S14](#mmc1){ref-type="supplementary-material"}). One colony had mutations in both copies of ME element bearing the G allele of rs953413 (G2; [Figure S15](#mmc1){ref-type="supplementary-material"}A) and two colonies had all the alleles of the ME elements mutated (all; [Figure S15](#mmc1){ref-type="supplementary-material"}B). In accordance with our previous results, the colonies with mutations in the predicted FOXA-binding sites (mut) had significantly decreased expression of *ELOVL2* compared with the control group (control) after normalization with reference genes *RSP18*, *ACTB,* and *GAPDH*, respectively ([Figures 6](#fig6){ref-type="fig"}D and [S16](#mmc1){ref-type="supplementary-material"}). Accordingly, the allelic imbalance in *ELOVL2* expression detected by rs2295601 AS-qPCR was significantly decreased in both group G1 and G2 compared with the control group in a dosage-dependent manner ([Figure 6](#fig6){ref-type="fig"}E). In addition, the two colonies grouped with all the copies of the ME elements being mutated (all) had relatively more conserved FOXA binding sites in the ME elements bearing the G allele of rs953413 compared with that of the A allele of rs953413 that led to significantly increased allelic imbalance in *ELOVL2* expression ([Figure S17](#mmc1){ref-type="supplementary-material"}). This suggested that the ME element encompassing rs953413 is a key regulatory region for *ELOVL2* expression.

The double gRNA strategy failed to directly mutate rs953413. We searched the rs953413 region again and designed allele-specific gRNA (AS-gRNA) that directly targets rs953413 to provide complementary evidence that rs953413 is essential for *ELOVL2* expression ([Figure 6](#fig6){ref-type="fig"}F). As rs953413 is the first nucleotide 3′ adjacent to PAM, which is part of the seed sequence essential for efficient gRNA binding, the designed AS-gRNA targeting rs953413 in theory should show high allelic preference in binding to the rs953413 region ([@bib34]). To prove our hypothesis, each AS-gRNA targeting rs953413 was coupled with the catalytically inactive Cas9 (dCas9) fused with either the activating VP64 domain (dCas9-VP64) or the suppressive KRAB domain (dCas9-KRAB) to be delivered into HepG2 cells by lentiviral transduction to test its effect on *ELOVL2* expression *in trans* ([@bib13]) ([Figure 6](#fig6){ref-type="fig"}G). The AS-gRNA targeting the G allele of rs953413 (G-gRNA) potently suppressed *ELOVL2* expression when coupled with the suppressive dCas9-KRAB, whereas the *ELOVL2* expression was significantly increased by G-gRNA coupled with dCas9-VP64 after normalization with reference genes *RSP18*, *ACTB,* and *GAPDH*, respectively ([Figures 6](#fig6){ref-type="fig"}H and [S18](#mmc1){ref-type="supplementary-material"}). The AS-gRNA targeting the A allele of rs953413 (A-gRNA) is less effective in regulating *ELOVL2* expression, which was only observed to significantly increase *ELOVL2* expression when coupled with dCas9-VP64 after normalization with *GAPDH* ([Figure S18](#mmc1){ref-type="supplementary-material"}B). However, the rs2295601 AS-qPCR clearly showed that both AS-gRNA displayed high allelic preference in affecting *ELOVL2* expression ([Figure 6](#fig6){ref-type="fig"}I). When coupled with dCas9-KRAB, each AS-gRNA preferentially suppressed the transcription of *ELOVL2* located on the same chromosome with target allele of rs953413. While coupling with dCas9-VP64, the *ELOVL2* transcript in linkage with respective allele of rs953413 was selectively activated by AS-gRNA.

We next coupled each AS-gRNA with wild-type Cas9 to directly introduce mutations to rs953413 to determine its effect on *ELOVL2* expression in HepG2 cells. The allelic imbalance in mutating rs953413 by each AS-gRNA was determined with rs953413 AS-qPCR, which can specifically quantify the relative amount of mutations introduced into each allele of rs953413. In accordance with our previous observations, the A allele of rs953413 was preferentially mutated by A-gRNA coupled with wild-type Cas9, whereas the G allele of rs953413 was preferentially mutated by G-gRNA compared with cells transduced with lentiCRISP v2 virus as control ([Figure 6](#fig6){ref-type="fig"}J). The expression of *ELOVL2* was observed to be significantly downregulated by mutations introduced to rs953413 by each AS-gRNA after normalization with reference genes *RSP18*, *ACTB,* and *GAPDH*, respectively ([Figures 6](#fig6){ref-type="fig"}K and [S19](#mmc1){ref-type="supplementary-material"}). Accordingly, preferentially introducing mutations to either allele of rs953413 significantly decreased the expression of its linked *ELOVL2* transcript determined by rs2295601 AS-qPCR ([Figure 6](#fig6){ref-type="fig"}L). These observations together with the results from double gRNA clearly demonstrated that rs953413 determines the enhancer activity of the identified ME element which further regulates *ELOVL2* expression.

Discussion {#sec3}
==========

We here demonstrate that rs953413 mediates the cooperative binding of HNF4α and FOXA1/FOXA2 to the evolutionarily conserved enhancer region, which acts as a key cis-regulatory element for *ELOVL2* expression. The G allele of rs953413 is preferentially bound by the complex formed by these TFs and increases the expression of *ELOVL2* that further increases the amount of LC-PUFAs synthesized ([Figure 6](#fig6){ref-type="fig"}M).

As members of the hepatocyte nuclear factor family, *HNF4α* and *FOXA1*/*FOXA2* are all essential TFs for normal liver function and their expression profile also showed high tissue specificities with a preference for the liver, pancreas, and kidney ([@bib19]). In accordance with the enhancer activity tightly regulated by the cooperation between FOXA1/FOXA2 and HNF4α, the rs953413 region showed tissue-specific enhancer features with both active chromatin marker H3K27ac and different TFs enriched mainly in liver HepG2 cells ([Figure S4](#mmc1){ref-type="supplementary-material"}). As liver is the most important organ for LC-PUFAs synthesis, the rs953413 region is supposed to be a key enhancer region for *ELOVL2* regulation in the liver, which further determines the systemic LC-PUFAs profiles. In accordance with the G allele of rs953413 upregulating *ELOVL2* expression in our study, SNPs in LD with the G allele of rs953413 were generally associated with a more efficient conversion of DHA from its precursors in GWAS ([@bib9], [@bib15], [@bib20], [@bib22], [@bib37]). The expression of *ELOVL2* in other tissues might be regulated by different mechanisms other than the rs953413 region illustrated by the observation that the A allele of rs953413 was associated with higher expression of *ELOVL2* in transformed fibroblasts (p = 1.5 × 10^−6^) from the GTEx project ([Figure S5](#mmc1){ref-type="supplementary-material"}) ([@bib1]). Additionally, it should be noted that an independent association between SNPs indexed by rs2281591 in the *ELOVL2* locus with DPA levels was observed in conditional analyses in both European- and Chinese-ancestry populations ([@bib14], [@bib20]). As these SNPs are not in LD with rs953413, this independent association signal suggests that there are other functional variants in this locus involved in *ELOVL2* regulation.

Previous studies have shown that ω-3 PUFAs, particularly DHA, may influence human health by exerting beneficial effects on many diseases such as cardiovascular disease, diabetes, cancer, depression, nonalcoholic fatty liver disease (NAFLD), and rheumatoid arthritis ([@bib17], [@bib25], [@bib35]). Recently, rs2236212, an intronic SNP of *ELOVL2*, was shown to be associated with NALFD in obese subjects ([@bib47]). Patients and animal models of nonalcoholic steatohepatitis (NASH), a severe form of NAFLD, showed marked decrease in hepatic ω-3 PUFAs levels, which may play a role in the development and progression of NASH ([@bib17], [@bib25]). Dietary intervention with ω-3 PUFAs DHA alone or EPA/DHA have shown indications of improvement in biomarkers related to NASH. The identified TFs in this study, including *FOXA1*/*FOXA2* and *HNF4α*, are tightly involved in NAFLD progression and are significantly downregulated in NAFLD ([@bib18], [@bib30], [@bib42], [@bib43]). This implies that downregulation of *ELOVL2* together with its upstream regulators *FOXA1*/*FOXA2* and *HNF4α* impairs hepatic DHA synthesis, which may play a role in the pathogenesis of NAFLD.

As a key enzyme in the *in vivo* synthesis of DHA, dysregulation of *ELOVL2* may also be involved in impairment of the systemic inflammatory process and diabetes progression ([@bib2], [@bib8], [@bib38], [@bib41]). However, further studies are needed to investigate the key TFs regulating *ELOVL2* in other cell types. It is interesting to note that *HNF4α*, *FOXA1*, and *FOXA2* have been extensively studied and appears to be involved in the progression of diabetes, and variations nearby *HNF4α* and *FOXA2* have been reported to be associated with diabetes related traits in GWAS ([@bib19], [@bib26]). *ELOVL2* may be an important downstream target in diabetes caused by dysregulation of these TFs.

In conclusion, we show that rs953413 affects LC-PUFAs levels by altering *ELOVL2* expression through FOXA1/FOXA2 and HNF4α cooperation. The results provide important mechanistic insights to the transcriptional machinery regulating *ELOVL2* in the liver and thereby circulating levels of PUFAs. Further studies are needed to elucidate the role of this pathway in diseases, liver diseases in particular.

Limitations of the Study {#sec3.1}
------------------------

Due to lack of detailed genotype and phenotype data at individual level in reported GWAS in this locus, the exact effect of rs953413 and other variations conditional on rs953413 on the reported phenotypes cannot be determined. As the exonic SNP rs2295601 is homozygous in PLC/PRF/5 cells, the changes in allelic imbalance in *ELOVL2* expression upon modulating the rs953413 locus cannot be determined in this cell line.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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